Reuters logo
BRIEF-Abeona Therapeutics receives pediatric disease designation for EB-101 gene therapy product for patients with Epidermolysis Bullosa
May 30, 2017 / 12:25 PM / 4 months ago

BRIEF-Abeona Therapeutics receives pediatric disease designation for EB-101 gene therapy product for patients with Epidermolysis Bullosa

May 30 (Reuters) - Abeona Therapeutics Inc:

* Abeona Therapeutics receives rare pediatric disease designation for eb-101 gene therapy product for patients with Epidermolysis Bullosa Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below